Vir Biotechnology Q3 2023 EPS $(1.22) Misses $(1.21) Estimate, Sales $2.64M Miss $10.24M Estimate
Portfolio Pulse from vinayak@benzinga.com
Vir Biotechnology reported Q3 2023 losses of $(1.22) per share, missing the analyst consensus estimate of $(1.21) by 0.83 percent. This is a 193.85 percent decrease over earnings of $1.30 per share from the same period last year. The company also reported quarterly sales of $2.64 million, missing the analyst consensus estimate of $10.24 million by 74.23 percent, a 99.30 percent decrease over sales of $374.56 million the same period last year.

November 02, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology's Q3 2023 earnings and sales significantly missed estimates and decreased compared to the same period last year.
The company reported a larger loss than expected and a significant decrease in sales compared to the same period last year. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100